Q2KHR3 (QSER1_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
Glutamine and serine-rich protein 1

Gene names

Name:

QSER1

Organism

Homo sapiens (Human)

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Protein attributes

Sequence length	1735 AA.
Sequence status	Complete.
Protein existence	Evidence at protein level

General annotation (Comments)

Post-translational modification	Phosphorylated upon DNA damage, probably by ATM or ATR. Ref.4 Ref.5 Ref.6 Ref.7 Ref.8 Ref.9
Sequence caution	The sequence AAI12936.1 differs from that shown. Reason: Contaminating sequence. Potential poly-A sequence. The sequence BAC86397.1 differs from that shown. Reason: Erroneous termination at position 1555. Translated as Leu.

Ontologies

Keywords
Coding sequence diversity	Alternative splicing Polymorphism
PTM	Phosphoprotein
Technical term	Complete proteome Reference proteome
Gene Ontology (GO)
None. [Check GOA]

Alternative products

This entry describes 2 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: Q2KHR3-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: Q2KHR3-2)

The sequence of this isoform differs from the canonical sequence as follows:
     243-481: Missing.
     1730-1735: VQQKCS → TGMLGEMQSVSVSSTRRSEQQNILEAGKSKIKVPVSGDC

Note: No experimental confirmation available.

Sequence annotation (Features)

	Feature key	Position(s)	Length	Description	Graphical view	Feature identifier
Molecule processing
	Chain	1 – 1735	1735	Glutamine and serine-rich protein 1		PRO_0000288933
Regions
	Compositional bias	120 – 527	408	Ser-rich
	Compositional bias	641 – 789	149	Gln-rich
Amino acid modifications
	Modified residue	606	1	Phosphotyrosine Ref.5
	Modified residue	613	1	Phosphoserine Ref.5
	Modified residue	931	1	Phosphoserine Ref.8
	Modified residue	949	1	Phosphothreonine Ref.7
	Modified residue	1211	1	Phosphoserine Ref.8
	Modified residue	1228	1	Phosphoserine Ref.6
	Modified residue	1230	1	Phosphoserine Ref.7 Ref.8
	Modified residue	1231	1	Phosphoserine Ref.6 Ref.7 Ref.8
	Modified residue	1239	1	Phosphoserine Ref.6
	Modified residue	1341	1	Phosphothreonine Ref.4 Ref.7 Ref.8 Ref.9
	Modified residue	1346	1	Phosphothreonine Ref.4 Ref.8
	Modified residue	1348	1	Phosphoserine Ref.7 Ref.8
Natural variations
	Alternative sequence	243 – 481	239	Missing in isoform 2.		VSP_039815
	Alternative sequence	1730 – 1735	6	VQQKCS → TGMLGEMQSVSVSSTRRSEQ QNILEAGKSKIKVPVSGDC in isoform 2.		VSP_039816
	Natural variant	385	1	V → I. Ref.1 Ref.3 Corresponds to variant rs1022586 [ dbSNP | Ensembl ].		VAR_056975
	Natural variant	644	1	Q → R. Corresponds to variant rs2297781 [ dbSNP | Ensembl ].		VAR_032535
	Natural variant	1018	1	N → S. Ref.1 Ref.3 Corresponds to variant rs7940077 [ dbSNP | Ensembl ].		VAR_032536
	Natural variant	1304	1	N → D. Corresponds to variant rs16923676 [ dbSNP | Ensembl ].		VAR_032537
Experimental info
	Sequence conflict	291	1	S → P in AK125391. Ref.1
	Sequence conflict	486	1	D → N in AK125391. Ref.1
	Sequence conflict	1075	1	R → G in AK125391. Ref.1
	Sequence conflict	1247	1	S → P in AK125391. Ref.1
	Sequence conflict	1258	1	D → E in AK125391. Ref.1

Sequences

	Sequence		Length	Mass (Da)
	Isoform 1 [UniParc]. Last modified October 5, 2010. Version 3. Checksum: 9FC28818DBB42A92	FASTA	1,735	189,972
	10 20 30 40 50 60 MNFLSTAESR TAQAAASGTT LLPQFRAPSW QTGMHSSAAT ELFATGPLPS TGTLPPSLSA 70 80 90 100 110 120 YQHPTTFSNR NFATTSPLVL QDSTFNTTSN GILSHHDPLL QIKTSQGTVP TALAFERLGS 130 140 150 160 170 180 SVLSNSIPPQ SSTYRSAQES APHLLQPQFS LLPSALGGSQ QTPQAYSSTL FTSSTASIER 190 200 210 220 230 240 ALLRECSVIK HHQRPSGTQS IQAQLTGSQH SLHSYLSNSS VVNFQETTRQ SSLSCSPIGD 250 260 270 280 290 300 STQVSNGGLQ QKTSQVSVEL AQSYSSAIPS SGYPPSTTKI KSCSTEQPLT STKTPKPQSI 310 320 330 340 350 360 IPPVQTLSYS KPLHNQSSVI SGQAQIYSTA QLPSLLSVSQ SQNYGLVQPH NVPSIVHSQV 370 380 390 400 410 420 YRSSKVEKLP PLYKTLTFSG SSQTVTPENQ TLNYSSNQQE VLSSVTNENY PAQTRDLSSV 430 440 450 460 470 480 SQSQSYSSGH SQGLSPVSQT QVSYSSQSQV LSVVSLSESY ASGESLTLTA PSLSYSSASR 490 500 510 520 530 540 AQNLPDSSPT QNYISMHSSQ NVQTQESSSP QSQKFLPAVQ SSSFASSTHC QTLQNNITSP 550 560 570 580 590 600 DPKSYAERKL DSDVYPSSKQ EDGFPMQELQ VLQPQASLES STQRLSDGEI NAQESTYKVS 610 620 630 640 650 660 KADDRYSQSV IRSNSRLEDQ VIGVALQASK KEESVVGSVT QLNQQIGQVN NAATLDLKNS 670 680 690 700 710 720 TNLIQTPQIR LNTKDLKQQH PLILKVHESK VQEQHDQIIN ASSQIQIPNH ALGHGHQASL 730 740 750 760 770 780 PNTQVLLDSA CDLQILQQSI LQAGLGQVKA SLQAQRVQSP QQIVHPFLQM EGHVIQSNGD 790 800 810 820 830 840 HSQQQLHPQN SEVMKMDLSE SSKPLQQHLT TKGHFSETNQ HDSKNQFVSL GSMCFPEAVL 850 860 870 880 890 900 LSDERNILSN VDDILAATAA ACGVTPTDFS KSTSNETMQA VEDGDSKSHF QQSLDVRHVT 910 920 930 940 950 960 SDFNSMTATV GKPQNINDTS LNGNQVTVNL SPVPALQSKM TLDQQHIETP GQNIPTKVTS 970 980 990 1000 1010 1020 AVVGPSHEVQ EQSSGPFKKQ SATNLESEED SEAPVDSTLN NNRNQEFVSS SRSISGENAT 1030 1040 1050 1060 1070 1080 SESEFTLGGD DSGVSMNPAR SALALLAMAQ SGDAVSVKIE EENQDLMHFN LQKKRAKGKG 1090 1100 1110 1120 1130 1140 QVKEEDNSNQ KQLKRPAQGK RQNPRGTDIY LPYTPPSSES CHDGYQHQEK MRQKIKEVEE 1150 1160 1170 1180 1190 1200 KQPEVKTGFI ASFLDFLKSG PKQQFSTLAV RMPNRTRRPG TQMVRTFCPP PLPKPSSTTP 1210 1220 1230 1240 1250 1260 TPLVSETGGN SPSDKVDNEL KNLEHLSSFS SDEDDPGYSQ DAYKSVSTPL TTLDATSDKK 1270 1280 1290 1300 1310 1320 KKTEALQVAT TSPTANTTGT ATTSSTTVGA VKQEPLHSTS YAVNILENIS SSESSKPIEL 1330 1340 1350 1360 1370 1380 DGLPSDQFAK GQDTVAIEGF TDEEDTESGG EGQYRERDEF VVKIEDIETF KEALKTGKEP 1390 1400 1410 1420 1430 1440 PAIWKVQKAL LQKFVPEIRD GQREFAATNS YLGYFGDAKS KYKRIYVKFI ENANKKEYVR 1450 1460 1470 1480 1490 1500 VCSKKPRNKP SQTIRTVQAK PSSSSKTSDP LASKTTTTKA PSVKPKVKQP KVKAEPPPKK 1510 1520 1530 1540 1550 1560 RKKWKEEFSS SQSDSSPEIH TSSSDDEEFE PPAPFVTRFL NTRAMKETFK SYMELLVSIA 1570 1580 1590 1600 1610 1620 LDPDTMQALE KSNDELLLPH MKKIDGMLND NRKRLLLNLH LDQSFKNALE SFPELTIITR 1630 1640 1650 1660 1670 1680 DSKAKSGGTA ISKIKMNGKA YNKKTLRTSK TTTKSAQEFA VDPEKIQLYS LYHSLHHYKY 1690 1700 1710 1720 1730 HVYLICKDEI SSVQKKNEDL GQEEIVQLCM KNVKWVEDLF EKFGELLNHV QQKCS
	Isoform 2 [UniParc]. Checksum: 811508C5F1B2FC4F	FASTA	1,529	168,003
	10 20 30 40 50 60 MNFLSTAESR TAQAAASGTT LLPQFRAPSW QTGMHSSAAT ELFATGPLPS TGTLPPSLSA 70 80 90 100 110 120 YQHPTTFSNR NFATTSPLVL QDSTFNTTSN GILSHHDPLL QIKTSQGTVP TALAFERLGS 130 140 150 160 170 180 SVLSNSIPPQ SSTYRSAQES APHLLQPQFS LLPSALGGSQ QTPQAYSSTL FTSSTASIER 190 200 210 220 230 240 ALLRECSVIK HHQRPSGTQS IQAQLTGSQH SLHSYLSNSS VVNFQETTRQ SSLSCSPIGD 250 260 270 280 290 300 STQNLPDSSP TQNYISMHSS QNVQTQESSS PQSQKFLPAV QSSSFASSTH CQTLQNNITS 310 320 330 340 350 360 PDPKSYAERK LDSDVYPSSK QEDGFPMQEL QVLQPQASLE SSTQRLSDGE INAQESTYKV 370 380 390 400 410 420 SKADDRYSQS VIRSNSRLED QVIGVALQAS KKEESVVGSV TQLNQQIGQV NNAATLDLKN 430 440 450 460 470 480 STNLIQTPQI RLNTKDLKQQ HPLILKVHES KVQEQHDQII NASSQIQIPN HALGHGHQAS 490 500 510 520 530 540 LPNTQVLLDS ACDLQILQQS ILQAGLGQVK ASLQAQRVQS PQQIVHPFLQ MEGHVIQSNG 550 560 570 580 590 600 DHSQQQLHPQ NSEVMKMDLS ESSKPLQQHL TTKGHFSETN QHDSKNQFVS LGSMCFPEAV 610 620 630 640 650 660 LLSDERNILS NVDDILAATA AACGVTPTDF SKSTSNETMQ AVEDGDSKSH FQQSLDVRHV 670 680 690 700 710 720 TSDFNSMTAT VGKPQNINDT SLNGNQVTVN LSPVPALQSK MTLDQQHIET PGQNIPTKVT 730 740 750 760 770 780 SAVVGPSHEV QEQSSGPFKK QSATNLESEE DSEAPVDSTL NNNRNQEFVS SSRSISGENA 790 800 810 820 830 840 TSESEFTLGG DDSGVSMNPA RSALALLAMA QSGDAVSVKI EEENQDLMHF NLQKKRAKGK 850 860 870 880 890 900 GQVKEEDNSN QKQLKRPAQG KRQNPRGTDI YLPYTPPSSE SCHDGYQHQE KMRQKIKEVE 910 920 930 940 950 960 EKQPEVKTGF IASFLDFLKS GPKQQFSTLA VRMPNRTRRP GTQMVRTFCP PPLPKPSSTT 970 980 990 1000 1010 1020 PTPLVSETGG NSPSDKVDNE LKNLEHLSSF SSDEDDPGYS QDAYKSVSTP LTTLDATSDK 1030 1040 1050 1060 1070 1080 KKKTEALQVA TTSPTANTTG TATTSSTTVG AVKQEPLHST SYAVNILENI SSSESSKPIE 1090 1100 1110 1120 1130 1140 LDGLPSDQFA KGQDTVAIEG FTDEEDTESG GEGQYRERDE FVVKIEDIET FKEALKTGKE 1150 1160 1170 1180 1190 1200 PPAIWKVQKA LLQKFVPEIR DGQREFAATN SYLGYFGDAK SKYKRIYVKF IENANKKEYV 1210 1220 1230 1240 1250 1260 RVCSKKPRNK PSQTIRTVQA KPSSSSKTSD PLASKTTTTK APSVKPKVKQ PKVKAEPPPK 1270 1280 1290 1300 1310 1320 KRKKWKEEFS SSQSDSSPEI HTSSSDDEEF EPPAPFVTRF LNTRAMKETF KSYMELLVSI 1330 1340 1350 1360 1370 1380 ALDPDTMQAL EKSNDELLLP HMKKIDGMLN DNRKRLLLNL HLDQSFKNAL ESFPELTIIT 1390 1400 1410 1420 1430 1440 RDSKAKSGGT AISKIKMNGK AYNKKTLRTS KTTTKSAQEF AVDPEKIQLY SLYHSLHHYK 1450 1460 1470 1480 1490 1500 YHVYLICKDE ISSVQKKNED LGQEEIVQLC MKNVKWVEDL FEKFGELLNH TGMLGEMQSV 1510 1520 SVSSTRRSEQ QNILEAGKSK IKVPVSGDC

References

[1]	"Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. , Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S. Nat. Genet. 36:40-45(2004) [PubMed: 14702039] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 82-1258 (ISOFORM 1), VARIANTS ILE-385 AND SER-1018. Tissue: Brain and Testis.
[2]	"Human chromosome 11 DNA sequence and analysis including novel gene identification." Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G. , Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S., Sakaki Y. Nature 440:497-500(2006) [PubMed: 16554811] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[3]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1696 (ISOFORM 1), VARIANTS ILE-385 AND SER-1018. Tissue: Uterus.
[4]	"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Cell 127:635-648(2006) [PubMed: 17081983] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1341 AND THR-1346, MASS SPECTROMETRY. Tissue: Cervix carcinoma.
[5]	"Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra." Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D. J. Proteome Res. 6:4150-4162(2007) [PubMed: 17924679] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-606 AND SER-613, MASS SPECTROMETRY. Tissue: Cervix carcinoma.
[6]	"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage." Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. Science 316:1160-1166(2007) [PubMed: 17525332] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1228; SER-1231 AND SER-1239, MASS SPECTROMETRY. Tissue: Embryonic kidney.
[7]	"A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed: 18669648] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-949; SER-1230; SER-1231; THR-1341 AND SER-1348, MASS SPECTROMETRY. Tissue: Cervix carcinoma.
[8]	"Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach." Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S. Anal. Chem. 81:4493-4501(2009) [PubMed: 19413330] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-931; SER-1211; SER-1230; SER-1231; THR-1341; THR-1346 AND SER-1348, MASS SPECTROMETRY. Tissue: Embryonic kidney.
[9]	"Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed: 19690332] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1341, MASS SPECTROMETRY. Tissue: Leukemic T-cell.
[10]	"Initial characterization of the human central proteome." Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J. BMC Syst. Biol. 5:17-17(2011) [PubMed: 21269460] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
+	Additional computationally mapped references.

Cross-references

Sequence databases
EMBL GenBank DDBJ	AK125391 mRNA. No translation available. AK126023 mRNA. Translation: BAC86397.1. Sequence problems. AC107939 Genomic DNA. No translation available. BC112935 mRNA. Translation: AAI12936.1. Sequence problems.
IPI	IPI00418991. IPI00847870.
RefSeq	NP_001070254.1. NM_001076786.1.
UniGene	Hs.369368.
3D structure databases
ProteinModelPortal	Q2KHR3.
ModBase	Search...
PTM databases
PhosphoSite	Q2KHR3.
Polymorphism databases
DMDM	308153569.
Proteomic databases
PeptideAtlas	Q2KHR3.
PRIDE	Q2KHR3.
Protocols and materials databases
StructuralBiologyKnowledgebase	Search...
Genome annotation databases
Ensembl	ENST00000399302; ENSP00000382241; ENSG00000060749.
GeneID	79832.
KEGG	hsa:79832.
UCSC	uc001mty.1. human. uc001mtz.1. human.
Organism-specific databases
CTD	79832.
GeneCards	GC11P032905.
H-InvDB	HIX0009534.
HGNC	HGNC:26154. QSER1.
HPA	HPA005682.
neXtProt	NX_Q2KHR3.
GenAtlas	Search...
Phylogenomic databases
eggNOG	prNOG12982.
GeneTree	ENSGT00440000037417.
HOGENOM	HBG444812.
HOVERGEN	HBG089439.
InParanoid	Q2KHR3.
OMA	QIYSTAQ.
OrthoDB	EOG4NGGM0.
Gene expression databases
ArrayExpress	Q2KHR3.
Bgee	Q2KHR3.
CleanEx	HS_QSER1.
Genevestigator	Q2KHR3.
Family and domain databases
ProtoNet	Search...
Other
NextBio	69477.

Entry information

Entry name

QSER1_HUMAN

Accession

Primary (citable) accession number: Q2KHR3
Secondary accession number(s): Q6ZU30, Q6ZUR5

Entry history

Integrated into UniProtKB/Swiss-Prot:	May 29, 2007
Last sequence update:	October 5, 2010
Last modified:	January 25, 2012
This is version 48 of the entry and version 3 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.